2014
DOI: 10.1038/ncomms6067
|View full text |Cite
|
Sign up to set email alerts
|

Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21CDKN1A

Abstract: Endoplasmic reticulum (ER) stress occurs in poorly perfused tissues and activates the p53 isoform p53/47 to promote G2 arrest via 14-3-3s. This contrasts with the p21 CDKN1A -dependent G1 arrest caused by p53 following DNA damage. It is not known how cells respond to conditions when both pathways are activated. Here we show that p53/47 prevents p53-induced p21 transcription during ER stress and that both isoforms repress p21 mRNA translation. This prevents p21 from promoting COP1-mediated 14-3-3s degradation a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

9
67
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 62 publications
(76 citation statements)
references
References 64 publications
9
67
0
Order By: Relevance
“…Results from recent studies have provided evidence that the expression of P21 exhibits an inverse correlation with ER-stress induction and CHOP expression ). This result is indicative of a role for this cell cycle regulator in the commitment of the UPR to the adaptive or the proapoptotic program that follows ER stress , Yi et al 2012, Mlynarczyk & Fåhraeus 2014. P21 is a cell cycle regulator that in addition to the inhibition of cell cycle progression also exhibits strong anti-apoptotic activities that can affect the decision about life or death of a cell under conditions associated with genotoxic stress (Blagosklonny 2002, Roninson 2002, Weiss 2003, Trimis et al 2008.…”
Section: Introductionmentioning
confidence: 99%
“…Results from recent studies have provided evidence that the expression of P21 exhibits an inverse correlation with ER-stress induction and CHOP expression ). This result is indicative of a role for this cell cycle regulator in the commitment of the UPR to the adaptive or the proapoptotic program that follows ER stress , Yi et al 2012, Mlynarczyk & Fåhraeus 2014. P21 is a cell cycle regulator that in addition to the inhibition of cell cycle progression also exhibits strong anti-apoptotic activities that can affect the decision about life or death of a cell under conditions associated with genotoxic stress (Blagosklonny 2002, Roninson 2002, Weiss 2003, Trimis et al 2008.…”
Section: Introductionmentioning
confidence: 99%
“…Cross-talk between the UPR and p53 has been reported in many studies (see examples in refs. [122][123][124][125], which may infl uence gene expression toward cell adaptation or induction of apoptosis, and thus determine cancer cell fate. For example, a recent report provided evidence suggesting that UPR signaling modulates the function of a p53 isoform ( 122 ).…”
Section: Er Stress and Dna Damage/repairmentioning
confidence: 99%
“…[122][123][124][125], which may infl uence gene expression toward cell adaptation or induction of apoptosis, and thus determine cancer cell fate. For example, a recent report provided evidence suggesting that UPR signaling modulates the function of a p53 isoform ( 122 ). In addition, ER stress may affect the cell cycle and protein translation in a p53-dependent manner ( 123,124 ).…”
Section: Er Stress and Dna Damage/repairmentioning
confidence: 99%
“…P21 is a cell-cycle regulator with strong anti-apoptotic activity produced by both cellautonomous and non-cell-autonomous mechanisms (Blagosklonny 2002, Roninson 2002, Weiss 2003, Trimis et al 2008. Recently, the suppression of P21 expression by the P53 isoform P53/47 during ER stress has been demonstrated and has been linked to the reduction of the apoptotic threshold during anticancer therapy (Mlynarczyk & Fåhraeus 2014). In this study, we explored the regulation of P21 through the transcription factor CHOP at the level of transcription and evaluated how P21 activity affects the sensitivity of cells to the ER stress inducer tunicamycin (TUN), the conventional anticancer agent doxorubicin (DOX), or a combination of the two.…”
Section: Introductionmentioning
confidence: 99%